N
NiKang Therapeutics
Privately-held biotech company focused on developing novel small molecule oncology drug discovery
About NiKang Therapeutics
NiKang Therapeutics is an early-stage biotech startup that operates in the oncology sector. The company's primary focus is on the discovery and development of innovative small molecule medicines to treat cancer. These medicines are designed to meet the needs of patients for whom current treatments are insufficient or ineffective.
The company's approach to drug discovery is driven by an in-depth understanding of disease biology and molecular pathways. This means they study the biological processes and mechanisms involved in the development of cancer to identify potential targets for their drugs. Their drug design is informed by the structure of these targets, allowing them to create drugs that can effectively interact with and influence these biological processes.
NiKang's business model is centered around the rapid and efficient discovery and advancement of proprietary drug candidates. These candidates are selected based on their pharmacological features, with the most promising ones being moved into clinical studies. The company's ultimate goal is to bring transformative medicines to patients in need, thereby creating a revenue stream through the sale of these innovative treatments.
In summary, NiKang Therapeutics is a biotech startup operating in the oncology sector, focused on the discovery and development of innovative small molecule medicines to meet unmet patient needs. Their approach is driven by deep insights into disease biology and molecular pathways, and they aim to rapidly and efficiently advance promising drug candidates into clinical studies.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | May 2021 | $200M | $382M | BlackRock · Matrix Partners China · Invus · Lilly Asia Ventures | — |
| SERIES BOther financing | Sep 2020 | $50M | $200M | Matrix Partners China · Lilly Asia Ventures · Casdin Capital · RTW Investments | ↗ |
Growth signals
Latest recorded traffic for NiKang Therapeutics is 1.8K monthly website visits, up 127.8% over the last three months. NiKang Therapeutics's team declined 9.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
NiKang Therapeutics in the Greenville ecosystem
The NiKang Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
CBC Group
Series A5 investors entered at this stage
Matrix Partners China
Lilly Asia Ventures
Casdin Capital
RTW Investments
Octagon Capital Partners
Series B and later16 investors entered at this stage
BlackRock
Invus
RA Capital Management
Surveyor Capital
HBM Healthcare Investments
Wellington Management
PFM Health Sciences
Cormorant Asset ManagementJanus Henderson Investors
Perceptive Advisors
Ally Bridge Group
EcoR1 Capital
Samsara BioCapital
Logos Capital- PCPavilion Capital
Octagon Capital Advisors
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about NiKang Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See NiKang Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









